51
Valentina Molteni, Xiaolin Li, Juliet Nabakka, David Archer Ellis, Beth Anaclerio, Enrique Saez, John Wityak: Compounds and compositions as lxr modulators. Irm, Genomics Institute Of The, Novartis Research Foundation, December 31, 2009: US20090325981-A1

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).


52
Hong Liu, Xiaohui He, Ha Soon Choi, Kunyong Yang, David H Woodmansee, Zhicheng Wang, David Archer Ellis, Boagen Wu, Yun He, Truc Ngoc Nguyen: Compounds and compositions as inhibitors of cannabinoid receptor 1 activity. Irm, September 6, 2012: US20120225869-A1

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).


53
Valentina Molteni, Xiaolin Li, Juliet Nabakka, David Archer Ellis, Beth Anaclerio, Enrique Saez, John Witak: Compounds and compositions as lxr modulators. Irm, August 23, 2012: US20120214812-A1

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).


54
Hong Liu, Xiaohui He, Ha Soon Choi, Kunyong Yang, David H Woodmansee, Zhicheng Wang, David Archer Ellis, Baogen Wu, Yun He, Truc Ngoc Nguyen: Compounds and compositions as inhibitors of cannabinoid receptor 1 activity. Novartis, Corporate Intellectual Property, October 1, 2009: US20090247517-A1

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).


55
Xiaohui He, Kunyong Yang, Hong Liu, David Archer Ellis: Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity. Irm, Genomics Institute Of The, Novartis Research Foundation, October 1, 2009: US20090247556-A1

The invention provides compounds of formula (Ia), (Ic), (Ig) and (Ik), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).


56

57
ELLIS David Archer, MOHAPATRA Suchismita, NAMIL Abdelmoula, CHEN Hwang Hsing, SEVERNS Byron, BELANGER David B: [fr] COMPOSÉS ANTIMICROBIENS DE CARBOLINE, [en] ANTIMICROBIAL CARBOLINE COMPOUNDS. ALCON RESEARCH, FLANIGAN Mark E, May 10, 2013: WO/2013/067409

[en] The invention provides compositions comprising carboline compounds for treating infections such as viral conjunctivitis. The invention also provides methods for treating of other infections, including ocular infections. More particularly, the present invention relates to compositions comprising ...


58
He Xiaohui, Yang Kunyong, Liu Hong, Ellis David Archer: Azolopyrimidines as inhibitors of cannabinoid 1 activity. Irm, Huang Gesheng, Lin Bainan, June 10, 2009: CN200780019818

The invention provides compounds of formula (Ia), (Ic), (Ig) and (Ik), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).


59
Molteni Valentina, Li Xiaolin, Nabakka Juliet, Ellis David Archer, Anaclerio Beth, Saez Enrique, Wityak John: Compounds and compositions as lxr modulators. Irm, huang gesheng lin bainan, February 21, 2007: CN200580004677

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).


60
Liu Hong, He Xiaohui, Choi Ha Soon, Yang Kunyong, Woodmansee David, Wang Zhicheng, Ellis David Archer, Wu Baogen, He Yun, Nguyen Truc Ngoc: Compounds and compositions as inhibitors of cannabinoid receptor 1 activity. Irm, huangge sheng anpei dong, October 3, 2007: CN200580036890

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).